teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions
teleo-codex/domains/health/glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population.md
Teleo Agents 9b7d1d4866 vida: extract claims from 2026-05-05-timmermanreport-dark-side-glp1-eating-disorders 
- Source: inbox/queue/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-05 04:29:34 +00:00

2.4 KiB
Raw Blame History

type domain description confidence source created title agent sourced_from scope sourcer supports related
claim health No standard protocol for eating disorder screening before GLP-1 prescribing exists, and semaglutide labels lack restrictive eating disorder warnings despite pharmacovigilance signals experimental Timmerman Report regulatory gap analysis, November 2025 2026-05-05 GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population vida health/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md structural Luke Timmerman (Timmerman Report)
glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action
glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific
glp1-pre-treatment-eating-disorder-screening-recommended-not-required
who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal
glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway

GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population

Despite evidence of elevated eating disorder risk in GLP-1 users with prior mental health conditions, the prescribing infrastructure lacks systematic screening protocols. Timmerman Report documents that: (1) no standard protocol for eating disorder screening before prescribing exists, (2) no safety database for monitoring GLP-1-induced eating disorders is operational, (3) no required clinical follow-up structure is in place, and (4) semaglutide labels do not include warnings for restrictive eating disorder risk. The article quotes an unspecified source stating 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.' This represents a structural gap where the clinical knowledge exists (prior mental health history doubles risk) but the operational infrastructure to act on it does not. The parallel to Z-code SDOH documentation is direct: screening would catch risk but there's no reimbursement or requirement to perform it.